29241-62-1

Basic information

• Product Name: 5-Bromo-6-chloronicotinic acid
• Synonyms: 5-BROMO-6-CHLORONICOTINIC ACID;5-BROMO-6-CHLOROPYRIDINE-3-CARBOXYLIC ACID;5-Bromo-6-chloronicotinic acid 97%;5-Bromo-6-chloronicotinic acid ,97%;5-Bromo-6-chloro-3-pyridinecarboxylicacid;3-Bromo-2-chloropyridine-5-carboxylic acid;3-Pyridinecarboxylic acid, 5-bromo-6-chloro-;5-Bromo-6-chloropyridine-3-carboxylic acid, 3-Bromo-5-carboxy-2-chloropyridine
• CAS NO: 29241-62-1
• Molecular Formula: C₆H₃BrClNO₂
• Molecular Weight: 236.45
• Product Categories: Acids and Derivatives;Heterocycles;pharmacetical;Carboxylic Acids;Pyridines;API intermediates;Pyridine;Carboxylic Acids
• Mol File: 29241-62-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 166-168°C
• Boiling Point: 370 °C at 760 mmHg
• Flash Point: 177.5 °C
• Appearance: /
• Density: 1.917 g/cm³
• Vapor Pressure: 3.98E-06mmHg at 25°C
• Storage Temp.: Room temperature.
• Solubility: soluble in Methanol
• PKA: 2.85±0.10(Predicted)
• CAS DataBase Reference: 5-Bromo-6-chloronicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-6-chloronicotinic acid(29241-62-1)
• EPA Substance Registry System: 5-Bromo-6-chloronicotinic acid(29241-62-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37/38
• HazardClass: IRRITANT
• Hazardous Substances Data: 29241-62-1(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C6H3BrClNO2/c7-4-1-3(6(10)11)2-9-5(4)8/h1-2H,(H,10,11)/p-1

Upstream product

• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 
• 5006-66-6 6-hydroxynicotinic acid 
• 17282-03-0 3-bromo-2-chloro-5-methyl-pyridine 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 41668-13-7 5-bromo-6-hydroxy-3-pyridinecarboxylic acid 

Downstream Products

• 405939-59-5 (5-bromo-6-chloropyridin-3-yl)carbamic acid tert-butyl ester 
• 882516-38-3 (6-{5-[tert-butoxycarbonyl-(3-hydroxy-propyl)-amino]-2-chloro-pyridin-3-yl}-pyrazin-2-yl)-(3-chloro-phenyl)-carbamic acid tert-butyl ester 
• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 
• 912454-75-2 6-benzyloxy-5-bromo-3-pyridinecarboxylic acid 
• 952063-30-8 ethyl 5-bromo-6-chloronicotinate 
• 912454-34-3 5-bromo-6-(2-methoxyethoxy)-3-pyridinecarboxylic acid 
• 1012792-55-0 6-chloro-5-(4-chlorophenyl)-3-pyridinecarboxylic acid methyl ester 
• 1018782-80-3 6-chloro-5-(4-fluorophenyl)-3-pyridinecarboxylic acid methyl ester 
• 1012792-56-1 6-chloro-5-(4-chlorophenyl)-3-pyridinecarboxylic acid 
• 1018782-81-4 6-chloro-5-(4-fluorophenyl)-3-pyridinecarboxylic acid 
• 1018782-76-7 5-(4-chlorophenyl)-6-(cyclopropylmethoxy)-3-pyridinecarboxylic acid 
• 1018782-82-5 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-3-pyridinecarboxylic acid 
• 912454-36-5 5-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(phenylmethoxy)-3-pyridine carboxamide 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF

Provided are a substituted heterocyclic amide compound having a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the

Iron-Catalyzed Amination of Strong Aliphatic C(sp3)-H Bonds

A concept for intramolecular denitrogenative C(sp3)-H amination of 1,2,3,4-tetrazoles bearing unactivated primary, secondary, and tertiary C-H bonds is discovered. This catalytic amination follows an unprecedented metalloradical activation mechanism. The utility of the method is showcased with the short synthesis of a bioactive molecule. Moreover, an initial effort has been embarked on for the enantioselective C(sp3)-H amination through the catalyst design. Collectively, this study underlines the development of C(sp3)-H bond functionalization chemistry that should find wide application in the context of drug discovery and natural product synthesis.

6-alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds

We identified 6-alkoxy-5-aryl-3-pyridinecarboxamides as potent CB1 receptor antagonists with high selectivity over CB2 receptors. The series was optimized to reduce lipophilicity compared to rimonabant to achieve peripherally active molecules with minimal central effects. Several compounds that showed high plasma exposures in rats were evaluated in vivo to probe the contribution of central vs peripheral CB1 agonism to metabolic improvement. Both rimonabant and 14g, a potent brain penetrant CB1 receptor antagonist, significantly reduced the rate of body weight gain. However, 14h, a molecule with markedly reduced brain exposure, had no significant effect on body weight. PK studies confirmed similarly high exposure of both 14h and 14g in the periphery but 10-fold lower exposure in the brain for 14h. On the basis of these data, which are consistent with reported effects in tissue-specific CB1 receptor KO mice, we conclude that the metabolic benefits of CB1 receptor antagonists are primarily centrally mediated as originally believed.